Physician

Srivalli Gopaluni, M.D.

According to 2025 Medicare claims, Srivalli Gopaluni, M.D. (NPI: 1427208990) practices hematology/oncology in the Spokane-Spokane Valley, WA market, with the plurality of this provider's patient population coming from Spokane, WA. This provider's primary affiliated billing organization is CANCER CARE NORTHWEST CENTERS P S (NPI: 1922072081; TIN: 911007627) and primary practice location at 99218-1246. Gopaluni is affiliated with the Collaborative ACO 30, LLC (ACO ID: A5483), participating under the MSSP model.

Gopaluni's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 345 traditional Medicare patients, billed 159,195 HCPCS/CPT codes, and received $2,933,574 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,107 prescription claims across 193 beneficiaries totaling $1,965,575 in drug costs, led by Verzenio (Abemaciclib). 2023 DME data shows 11 claims. Open Payments data shows 26 records totaling $5,115. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $2,153,226 and ending at $2,933,574. Concurrently, Part D prescription costs have risen steadily, from $716,080 to $1,965,575. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $14,710 to $1,471.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	868	276,431	$2,153,226
2016	918	319,344	$2,758,858
2017	985	337,209	$3,593,233
2018	1,075	450,599	$4,469,409
2019	764	354,346	$3,478,936
2020	635	270,160	$3,218,007
2021	537	276,993	$2,971,737
2022	500	243,038	$3,788,521
2023	467	207,559	$3,289,936
2024	345	159,195	$2,933,574

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	216	1,577	$716,080
2016	245	1,915	$883,434
2017	308	2,274	$990,856
2018	356	2,087	$959,944
2019	306	1,485	$901,471
2020	252	1,043	$865,589
2021	245	1,049	$907,056
2022	224	1,052	$1,069,475
2023	200	1,027	$1,497,277
2024	193	1,107	$1,965,575

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	28	176	$30,266
2016	66	260	$81,690
2017	37	137	$38,661
2018	23	146	$20,998
2019	24	109	$15,463
2020	22	106	$7,861
2021	N/R	49	$3,302
2022	N/R	13	$590
2023	N/R	11	$9,506
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	86	553	$103
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	193	597	$97
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	145	348	$12
36415	Insertion of needle into vein for collection of blood sample	183	870	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	154	808	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Verzenio	Abemaciclib	27	756	$325,671
Ibrance	Palbociclib	22	603	$254,911
Tasigna	Nilotinib Hcl	14	387	$244,946
Eliquis	Apixaban	28	840	$16,405
Nivestym	Filgrastim-Aafi	16	316	$11,721

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	25	$645	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$4,470	Mirati Therapeutics, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Srivalli Gopaluni, M.D.?

Tedicare shows public-source Medicare data for Srivalli Gopaluni, M.D. (NPI 1427208990), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Srivalli Gopaluni, M.D. have ACO affiliation data?

Srivalli Gopaluni, M.D. is shown with ACO affiliation data for Collaborative ACO 30, LLC (MSSP, ACO ID A5483).

What billing organization is linked to Srivalli Gopaluni, M.D.?

Srivalli Gopaluni, M.D. is linked to CANCER CARE NORTHWEST CENTERS P S (billing NPI 1922072081) in the available physician profile data.

Does Srivalli Gopaluni, M.D. have Open Payments data?

Srivalli Gopaluni, M.D. has 26 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.